Skip to content
ES
MARKETS / NASDAQ / PTCT
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

PTC Therapeutics, Inc. PTCT

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.7B
▲ 114.5% YoY
$682.6M
$702.3M
In brief

What this company does

PTC Therapeutics generates product revenue primarily from sales of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy outside of the United States, sales of Emflaza for the treatment of Duchenne muscular dystrophy in the United States, and, since the second half of 2025, sales of Sephience for the treatment of phenylketonuria. It has a therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. As of December 31, 2025, it had 991 employees and 56 consultants and contractors. It utilizes five specialty pharmacies to sell and distribute Sephience and Emflaza to patients. Its principal executive offices are located at 500 Warren Corp Center Drive, Warren, New Jersey.

Written from the business description in PTC THERAPEUTICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.7B
Revenue, FY2025 · full 15-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.7 · Net income 0.7
0.80B1.60B-0.25B-0.50B20112013201520172019202120232025
Compound annual growth
+35.3%
+35.4%
+47.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +35.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
39 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 50.1% · Net 39.4%
100%200%300%-200%-400%20112013201520172019202120232025
ROE
FY2021 · ROE -216.7%
-100%-200%20112013201520172019202120232025
Gross margin—
Operating margin50.1%
Net margin39.4%
Return on assets29.7%
EBITDAUSD 905.8M

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 702.3
250.0M500.0M-200.0M20112013201520172019202120232025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 2.9B
EquityUSD -205.3M
CashUSD 984.6M
Gross debtUSD 286.6M
Net debtUSD -698.0M
Current ratio2.35×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B1.70.80.90.70.50.40.30.30.20.10.00.00.00.00.1
Operating income $B0.9−0.3−0.4−0.4−0.4−0.4−0.2−0.1−0.1−0.1−0.2−0.1−0.0−0.00.0
EBITDA $B0.9−0.2−0.2−0.3−0.3−0.4−0.2−0.1−0.0−0.1−0.2−0.1−0.0−0.00.0
Income tax $B0.00.0−0.1−0.00.00.00.0−0.00.00.00.0−0.0··−0.0
Net income $B0.7−0.4−0.6−0.6−0.5−0.4−0.3−0.1−0.1−0.1−0.2−0.1−0.1−0.00.0
Free cash flow $B0.7−0.1−0.2−0.4−0.3−0.2−0.1−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0
EPS, diluted $7.78−4.73−8.37−7.79−7.43−6.64−4.27−2.75−2.02−4.17−5.07−2.97−5.1842.504.55
Dividend / sh $···············
Payout %···············
ROE %····−216.7−81.4−53.2−50.5−57.2−82.2−65.0−43.1−279.5··
Shares out B0.080.080.080.070.070.070.060.050.040.030.030.030.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 32 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image